Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LANOXIN PEDIATRIC vs ACYLANID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibition of Na+/K+ ATPase leading to increased intracellular calcium and positive inotropy.
Acylanid is a cardiac glycoside that inhibits the Na+/K+-ATPase pump, leading to increased intracellular sodium and calcium concentrations, which enhances myocardial contractility.
Heart failure,Atrial fibrillation,Atrial flutter
Heart failure,Atrial fibrillation,Atrial flutter
Adult: Oral loading dose 0.75-1.5 mg in divided doses over 24-48 hours. Maintenance: 0.125-0.5 mg once daily. Intravenous: Loading dose 0.5-1 mg over 10-20 minutes, then maintenance 0.125-0.5 mg once daily.
0.1 mg IV bolus over 5 minutes, followed by 0.1 mg IV after 1 hour if needed; then 0.1-0.2 mg orally every 6-8 hours for maintenance. Maximum cumulative dose: 0.4 mg IV.
Terminal elimination half-life is 36-48 hours in adults with normal renal function; prolonged to 3.5-5 days in anephric patients due to reduced renal clearance.
Terminal half-life 33–36 hours (anuric patients up to 110 hours); requires dose adjustment in renal impairment.
Hepatic via glucuronidation; substrate of P-glycoprotein; renal excretion of unchanged drug.
Hepatic metabolism via hydrolysis and conjugation; not significantly metabolized by CYP enzymes.
Renal excretion of unchanged drug accounts for 60-80% of elimination; nonrenal clearance is 20-40% (biliary/fecal).
Renal (≈70% as unchanged drug), biliary/fecal (≈30%)
20-30% bound to plasma proteins, primarily albumin.
25–30% bound to albumin.
Vd is 5-10 L/kg in adults, indicating extensive tissue binding; higher in infants (up to 16 L/kg) with reduced protein binding.
7.5–10 L/kg; wide distribution indicating extensive tissue binding.
Oral: 60-80% (Lanoxin Pediatric elixir 70-85%); variable due to first-pass metabolism and P-glycoprotein effects.
Oral: 70–85% (variable, dependent on gastrointestinal absorption).
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 25-50%; GFR <10 m L/min: reduce dose by 50-75% or consider alternative.
GFR <30 m L/min: reduce dose by 50% and extend dosing interval to every 12-24 hours. GFR 30-50 m L/min: consider 25% dose reduction. Monitor digoxin levels.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: avoid use or reduce dose by 50-75% with monitoring.
Child-Pugh Class B: reduce dose by 25-50%. Child-Pugh Class C: use with caution, reduce dose by 50% and monitor levels. Not recommended in severe hepatic impairment.
Oral loading: 10-20 mcg/kg in divided doses over 24 hours; maintenance: 5-10 mcg/kg once daily. IV loading: 10-15 mcg/kg; maintenance: 4-8 mcg/kg once daily. Monitor levels.
Loading dose: 10-15 mcg/kg IV over 5 minutes. Maintenance: 5-10 mcg/kg orally every 8-12 hours. Maximum daily dose: 250 mcg in children <2 years, 500 mcg in older children.
Reduced dose: initial maintenance 0.0625-0.125 mg once daily due to age-related renal impairment and increased sensitivity. Monitor renal function and serum digoxin levels.
Initiate with 50% of usual adult dose due to reduced renal function and increased sensitivity. Maximum loading dose: 0.2 mg IV. Maintenance: 0.1 mg every 12 hours. Monitor electrolytes and ECG.
Digitalis toxicity can cause severe arrhythmias; monitoring of serum digoxin levels required.
None.
Risk of toxicity in renal impairment, electrolyte disturbances, and drug interactions; monitor digoxin levels and ECG.
Risk of digitalis toxicity; monitor renal function and electrolytes; caution in hypokalemia, hypomagnesemia, and hypercalcemia.
Hypersensitivity to digoxin, ventricular fibrillation, digitalis toxicity.
Ventricular fibrillation,Hypersensitivity to cardiac glycosides,Digitalis toxicity
Avoid concurrent ingestion of high-fiber foods, as they may reduce absorption. Separate dosing by at least 2 hours from meals rich in bran, oats, or other fiber. Maintain consistent dietary potassium intake; both low and high potassium can affect digoxin toxicity. Grapefruit juice may increase absorption; avoid excessive consumption.
Avoid high-potassium foods (bananas, oranges, spinach) unless directed; hypokalemia increases toxicity. Take with food to reduce GI upset. Do not take with high-fiber meals as may reduce absorption.
First trimester: No evidence of increased risk of major malformations. Second/third trimester: Potential for fetal bradycardia, cardiac arrhythmias, and intrauterine growth restriction due to transplacental transfer and maternal hemodynamic changes.
Acylanid is a cardiac glycoside with limited data in pregnancy. First trimester: No specific malformations reported, but potential for fetal cardiac effects due to mechanism. Second and third trimesters: Maternal toxicity (arrhythmias, electrolyte disturbances) may cause fetal hypoxia or growth restriction. Avoid toxicity. Category C.
Digoxin is excreted into breast milk with an M/P ratio of approximately 0.6–0.9. Levels are low (typically <1 ng/m L) and considered compatible with breastfeeding; however, monitor infant for signs of toxicity including bradycardia and feeding difficulties.
Acylanid is excreted into breast milk in low amounts (M/P ratio not established; estimated <1% of maternal dose). No adverse effects reported in nursing infants. Use with caution, monitor infant for bradycardia or arrhythmias.
Due to increased volume of distribution and renal clearance in pregnancy, higher doses (up to 30–50% increase) may be required to maintain therapeutic serum levels. Monitor serum digoxin concentrations and titrate to therapeutic range (0.5–0.9 ng/m L in heart failure; 0.8–2.0 ng/m L for arrhythmias).
Increased volume of distribution and renal clearance in pregnancy may reduce serum levels; monitor drug levels and adjust dose to maintain therapeutic range (0.5-2 ng/m L). Start at lower doses if hypokalemia or preeclampsia present.
Lanoxin Pediatric (digoxin) requires monitoring of renal function and serum electrolytes (especially potassium and magnesium) due to narrow therapeutic index. Check digoxin levels 6-8 hours after dose; therapeutic range 0.8-2.0 ng/m L. Avoid concurrent use with drugs that affect renal function or electrolyte balance.
Acylanid (lanatoside C) is a digitalis glycoside with rapid onset (IV 10-30 min) and moderate duration; use in atrial fibrillation with rapid ventricular response, especially in acute settings. Monitor renal function due to renal elimination; toxicity risk increases with hypokalemia, hypomagnesemia, hypercalcemia. Adjust dose in renal impairment (Cr Cl <50 m L/min). Therapeutic drug monitoring: target serum level 0.5-2 ng/m L (drawn >6-8 hours post-dose).
Take exactly as prescribed at the same time each day. Do not double the dose if you miss one.,Do not stop taking without consulting your doctor. Sudden withdrawal may worsen heart condition.,Watch for signs of toxicity: nausea, vomiting, diarrhea, vision changes (blurring, yellow-green halos), confusion, irregular heartbeat.,Keep all appointments for blood tests to monitor levels and kidney function.,Contact your doctor before taking any new medications, including over-the-counter drugs and supplements.,Limit alcohol and avoid potassium-sparing diuretics unless prescribed. Maintain consistent dietary intake of potassium-rich foods.
Take exactly as prescribed; do not skip doses or double up. Missed dose: take if within 12 hours, otherwise skip.,Monitor for signs of toxicity: nausea, vomiting, diarrhea, visual disturbances (yellow-green halos, blurred vision), confusion, irregular heartbeat.,Avoid OTC medications without consulting prescriber, especially antacids, laxatives, and antiarrhythmics.,Keep regular appointments for blood tests (digoxin level, kidney function, electrolytes).,Report weight gain >2 lbs/day, swelling, shortness of breath, or palpitations.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LANOXIN PEDIATRIC vs ACYLANID, answered by our medical review team.
LANOXIN PEDIATRIC is a Cardiac Glycoside that works by Inhibition of Na+/K+ ATPase leading to increased intracellular calcium and positive inotropy.. ACYLANID is a Cardiac Glycoside that works by Acylanid is a cardiac glycoside that inhibits the Na+/K+-ATPase pump, leading to increased intracellular sodium and calcium concentrations, which enhances myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LANOXIN PEDIATRIC and ACYLANID depend on the specific clinical indication. These are both Cardiac Glycoside agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LANOXIN PEDIATRIC is: Adult: Oral loading dose 0.75-1.5 mg in divided doses over 24-48 hours. Maintenance: 0.125-0.5 mg once daily. Intravenous: Loading dose 0.5-1 mg over 10-20 minutes, then maintenance 0.125-0.5 mg once daily.. The standard adult dose of ACYLANID is: 0.1 mg IV bolus over 5 minutes, followed by 0.1 mg IV after 1 hour if needed; then 0.1-0.2 mg orally every 6-8 hours for maintenance. Maximum cumulative dose: 0.4 mg IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LANOXIN PEDIATRIC and ACYLANID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LANOXIN PEDIATRIC is classified as Category C. First trimester: No evidence of increased risk of major malformations. Second/third trimester: Potential for fetal bradycardia, cardiac arrhythmias, and intrauterine growth restric. ACYLANID is classified as Category C. Acylanid is a cardiac glycoside with limited data in pregnancy. First trimester: No specific malformations reported, but potential for fetal cardiac effects due to mechanism. Secon. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.